Posts Tagged: Paul Santerre
Making medical devices that address the challenge of delivering safe care to patients is standard procedure at the Institute of Biomaterials & Biomedical Engineering (IBBME). Just ask Professor Paul Santerre, IBBME Director, who developed Endexo Technology through his spin-off company, Interface…
On the morning of September 27, faculty members and industry came together to discuss nanotechnology. Supported by NSERC and co-hosted by MITACS, the NSERC Nanotechnology Connector Breakfast was a chance for U of T researchers – particularly engineering researchers –…
Another technology commercialization success story emerges from U of T. Interface Biologics Inc (IBI), a company founded by Professor Paul Santerre, Director of the Institute of Biomaterials & Biomedical Engineering (IBBME), announced the successful conclusion of a licensing evaluation period…
Professors Tom Chau and Dr. Albert Yee of the Institute of Biomaterials & Biomedical Engineering (IBBME) were honoured at a gala ceremony at the University of Toronto Faculty of Medicine’s Annual Education Achievement Celebration on April 26. Professor Chau, core…
April 6, 2011 A new Clinical Engineering concentration within the Institute of Biomaterials & Biomedical Engineering‘s PhD program has been approved for launch in September 2011. The new concentration, for doctoral candidates with an undergraduate engineering degree, will emphasize enhancing…
University of Toronto spinoff company Interface Biologics Inc. has announced the signing of an evaluation and exclusive license option agreement with Fresenius Medical Care, the world’s largest integrated provider of dialysis products and services. Under the agreement, Fresenius Medical Care…
Showing 31 - 36 of 36 results